Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Benign-by-Design SAHA Analogues for Human and Animal Vector-Borne Parasitic Diseases.

ACS medicinal chemistry letters·2024
Same author

HDAC inhibitors: a 2013-2017 patent survey.

Expert opinion on therapeutic patents·2018
See all related articles

Related Experiment Video

Updated: Jul 19, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

425

Aptamers Targeting the PD-1/PD-L1 Axis: A Perspective.

Philippe Bertrand1

  • 1University of Poitiers, IC2MP UMR 7285 CNRS, 4 rue Michel Brunet B27, TSA 51106, 86073 Poitiers cedex 9, France.

Journal of Medicinal Chemistry
|August 10, 2023
PubMed
Summary

Oligonucleotide aptamers offer a novel approach to immuno-oncology by blocking immune checkpoints like PD-1/PD-L1. These molecules show promise in cancer therapy and diagnostics, with ongoing research into enhancing their stability and expanding their applications.

More Related Videos

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.3K
Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
09:40

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

15.2K

Related Experiment Videos

Last Updated: Jul 19, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

425
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.3K
Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
09:40

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

15.2K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Immunology

Background:

  • Aptamers are nucleic acid or peptide molecules that can bind to a specific target molecule.
  • They are increasingly explored as alternatives to antibodies in various biological applications.
  • Immune checkpoints, such as PD-1 and PD-L1, are critical targets in immuno-oncology.

Purpose of the Study:

  • To provide an overview of aptamer development for targeting immune checkpoint modulators PD-1 and PD-L1.
  • To discuss the potential of aptamers in immuno-oncology and related therapeutic strategies.
  • To explore analogous aptamer strategies for other immune-related targets.

Main Methods:

  • Systematic Evolution of Ligands by Exponential Enrichment (SELEX) is the primary method for aptamer identification.
  • Modifications to the SELEX process can be employed for specific aptamer applications.
  • Delivery strategies are being investigated to manage aptamers' limited plasma stability.

Main Results:

  • Aptamers demonstrate high affinity binding to diverse targets, including proteins like PD-1 and PD-L1.
  • Aptamers can effectively block PD-1/PD-L1 interactions, representing a promising avenue for immuno-oncology.
  • Aptamers are applicable in both therapeutic interventions and novel assay technologies.

Conclusions:

  • Aptamers represent a significant advancement in immuno-oncology, offering a versatile alternative to traditional therapeutics.
  • Further research into aptamer stability and delivery is crucial for clinical translation.
  • The potential applications of aptamers extend beyond PD-1/PD-L1 to other immune-related targets, broadening their therapeutic scope.